Close Menu

NEW YORK (GenomeWeb) – Synthetic biology firm Evonetix announced today that it has closed a $12.3 million financing round.

The financing was co-led by Data Collective and Draper Esprit, and included Morningside Group along with existing investors Providence Investment Company, Cambridge Consultants, Rising Tide Fund, and Civilization Ventures. Evonetix was spun out of Cambridge Consultants in 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.